Eprenetapopt
- Generic Name
- Eprenetapopt
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17NO3
- CAS Number
- 5291-32-7
- Unique Ingredient Identifier
- Z41TGB4080
- Background
Eprenetapopt has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.
- Associated Conditions
- -
- Associated Therapies
- -
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04990778
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath